Replies to post #4938 on Cyclo Therapeutics Inc (CYTH)

[Lazarus]

Why the lol?

I continue to correct you regarding what I said about .25 which has to do with the warrants to be exercised.

When it comes to price there is no need set the bar on the downside to .25 (at last count I had 84 stocks worth ZERO in my portfolios).

Let me remind you of something:

_______________

Vtesse Inc. raises $25M Series A led by NEA

Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.

The series was led by New Enterprise Associates, along with Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.

The launch of Vtesse, which will be based in Gaithersburg, is the first such company to come out of Cambridge, Massachusetts-based Cydan Development, which is working to spin out additional companies with a focus on rare diseases with few viable treatments.

"We're very optimistic this could be an important therapeutic option for children," Vtesse CEO Ben Machielse told me.

The National Institute of Health has transferred to Vtesse exclusive worldwide rights to cyclodextrin, delta-tocopherol and derivatives of tocopherol, all of which have been under development at NIH for the treatment of lysosomal storage diseases.

Vtesse will use the funding to conduct a clinical program for VTS-270, a formulation of 2-hydroxypropyl-beta-cyclodextrin to treat a form of Niemann-Pick disease, a lyosomal storage disorder
_________________


The NIH has given its Imprimatur to VTESSE.

There is no question in my mind that Vtesse has leaped-frogged over CTDH.

This is now a David and Goliath story.

As a shareholder of the CTDH I would be happy to see CTDH take the lead and win... because I have no financial interest in VTESSE. Is it possible for CTDH to win this race? Sure it possible. Is it PROBABLE???? I think not.

Let's remember that last year CTDH over trebled their professional fees:

Professional fees (2014)---> 432,993

(2013)---> 142,860

while simultaneously achieving LOWER cyclodextrin sales.

This news looks to me like its about the hiring of more professionals to help CTDH stay in the race.

So now... we watch and wait.

Happy Trading